Accessibility Menu
CannaPharmaRX logo

CannaPharmaRX(OTC) CPMD

Current Price$0.00
Market Cap$1.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)-100%
5 Year-96%
1 Year-28%
1 Month-16%
CannaPharmaRX last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-24
CannaPharmaRX stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+16.67%USD 0.002026-07-17
1 month-16%USD 0.002026-06-24
3 month-47.5%USD 0.002026-04-24
Year to date-59.62%USD 0.012025-12-31
1 year-27.59%USD 0.002025-07-24
3 year-85%USD 0.012023-07-21
5 year-95.63%USD 0.052021-07-23
Since inception-100%USD 600.001999-10-29

CannaPharmaRX Financials at a Glance

Market Cap

$1.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.65M

Net Income (TTM)

-$10.82M

EPS (TTM)

-$0.02

P/E Ratio

-0.13

Dividend

$0.00

Beta (Volatility)

-920.01 (Low)

Price

$0.00

Volume

10,400

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Nov 14, 2025

CPMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CannaPharmaRX

CannaPharmaRX grows and sells cannabis for medical and pharmaceutical use. Its products help pharmaceutical companies and distributors meet demand for regulated cannabis. The company supplies bulk cannabis to partners in Canada, Germany, and Israel.

Products and Services

  • Dried cannabis flower: Main product, sold in bulk to pharmaceutical distributors.
  • Trim shake: Byproduct of flower production, used for extracts and lower-cost products.

Growth and Expansion

  • Acquired and developed a 55,000 square foot cultivation facility in Cremona, Alberta in 2022.
  • Entered German and Israeli markets for bulk cannabis sales (2024–2025).
  • Partnered with LTB Management in 2024 to build a European sales network and e-commerce platform.
  • Secured financing and operational support from Koze Investments in 2024–2025.
  • Applied for or planned to apply for EU-GMP certification to enable direct shipments to the European Union.

What Makes CannaPharmaRX Special

CannaPharmaRX focuses on international bulk sales, especially to Germany and Israel. The company holds multiple cultivation and processing licenses, supporting exports to regulated markets. Its single large facility allows for centralized production and quality control.

Five Things You Need to Know

  • Revenue was $1.36 million in 2025, up 66.1% from 2024.
  • Q3 2025 revenue was $656,606, up 110.3% from Q3 2024.
  • 92% of 2025 revenue came from two customers: one in Germany, one in Israel.
  • Net loss was $11.13 million in 2025, compared to $9.91 million in 2024.
  • Cash was $1,804 at year-end 2025, with a $30.2 million working capital deficit.

Bottom Line

CannaPharmaRX has shifted from domestic to international sales, focusing on bulk cannabis exports. The company faces financial challenges but continues to pursue growth in regulated overseas markets.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

26

CEO

Constantine Nkafu

Website

www.cannapharmarx.com

Headquarters

Calgary, AB T2P 5C5, CA

CPMD Financials

Key Financial Metrics (TTM)

Gross Margin

-120.40%

Operating Margin

-202.65%

Net Income Margin

-654.20%

Return on Equity

41.03%

Return on Capital

N/A

Return on Assets

-164.46%

Earnings Yield

-7.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

678.50M

Volume

10.40K

Avg. Volume

172.80K

Financials (TTM)

Gross Profit

-$1.99M

Operating Income

-$3.35M

EBITDA

-$8.23M

Operating Cash Flow

-$431.38K

Capital Expenditure

$187.72K

Free Cash Flow

-$436.90K

Cash & ST Invst.

$633.00

Total Debt

$20.97M

CannaPharmaRX Performance Analysis

CannaPharmaRX annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 820,137N/A
20252025-12-31USD 1,362,16366.1%
CannaPharmaRX sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-30.9%
Q32025-09-30183.5%
Q42025-12-31-78.9%
Q12026-03-31352.6%
CannaPharmaRX annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.04-65.8%
20232023-12-31USD 0.01N/A
20242024-12-31USD -0.02N/A
20252025-12-31USD -0.026.3%
CannaPharmaRX sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-110.0%
Q32025-09-30-4.8%
Q42025-12-31-422.7%
Q12026-03-3194.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$627.46K

+87.1%

Gross Profit

-$409.45K

+18.6%

Gross Margin

-65.26%

N/A

Market Cap

$1.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$54.80K

N/A

Employees

26

N/A

Net Income

-$382.02K

+44.7%

EBITDA

$405.14K

+917.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$633.00

-47.6%

Total Debt

$20.97M

+25.1%

Accounts Receivable

$26.01K

-90.9%

Inventory

$902.91K

-5.1%

Long Term Debt

$5.36M

+10.6%

Short Term Debt

$15.61M

+31.0%

Return on Assets

-1.64%

N/A

Return on Invested Capital

13.46%

N/A

Free Cash Flow

-$243.66K

+59.5%

Operating Cash Flow

-$243.66K

+59.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EXMTAnything Technologies Media, Inc.
$0.00+0.00%
PLSHPanacea Life Sciences Holdings, Inc.
$0.08+0.00%
CBDYTarget Group Inc.
$0.00+0.00%
MSTHMystic Holdings, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About CPMD

What is the current price of CannaPharmaRX?

CannaPharmaRX is trading at $0.00 per share.

What is the 52-week range for CannaPharmaRX?

Over the past 52 weeks, CannaPharmaRX has traded between $0.00 and $0.01.

How much debt does CannaPharmaRX have?

As of the most recent reporting period, CannaPharmaRX reported total debt of $20.97M.

How much cash does CannaPharmaRX have on hand?

CannaPharmaRX reported $633.00 in cash and cash equivalents in its most recent financial results.

What is CannaPharmaRX’s dividend yield?

CannaPharmaRX does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services